CN111378783A - Novel coronavirus 2019-nCoV nucleic acid kit and virus nucleic acid collection method - Google Patents
Novel coronavirus 2019-nCoV nucleic acid kit and virus nucleic acid collection method Download PDFInfo
- Publication number
- CN111378783A CN111378783A CN202010141882.9A CN202010141882A CN111378783A CN 111378783 A CN111378783 A CN 111378783A CN 202010141882 A CN202010141882 A CN 202010141882A CN 111378783 A CN111378783 A CN 111378783A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- ncov
- virus
- positive
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 57
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 41
- 241000700605 Viruses Species 0.000 title claims abstract description 41
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 38
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 38
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 38
- 239000000523 sample Substances 0.000 claims abstract description 66
- 238000001514 detection method Methods 0.000 claims abstract description 36
- 238000007847 digital PCR Methods 0.000 claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 11
- 230000003321 amplification Effects 0.000 claims abstract description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 9
- 238000011002 quantification Methods 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000003908 quality control method Methods 0.000 claims description 12
- 238000000137 annealing Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 abstract description 7
- 239000012295 chemical reaction liquid Substances 0.000 abstract description 7
- 208000024794 sputum Diseases 0.000 abstract description 7
- 210000003802 sputum Anatomy 0.000 abstract description 7
- 241000711573 Coronaviridae Species 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 3
- 208000025721 COVID-19 Diseases 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000005070 sampling Methods 0.000 abstract description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 10
- 210000003800 pharynx Anatomy 0.000 description 6
- 241000709661 Enterovirus Species 0.000 description 5
- 241001112090 Pseudovirus Species 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a novel coronavirus 2019-nCoV nucleic acid kit and a virus nucleic acid acquisition method, wherein a specific primer and a fluorescent probe are designed for detecting novel coronavirus 2019-nCoV nucleic acid in a sample according to the novel coronavirus 2019-nCoV ORF1ab and N gene serving as amplification target regions; combining the prepared Super premix reaction liquid A with the Super premix reaction liquids B and C, performing Digital PCR absolute quantification on 2019-nCoV nucleic acid RNA by adopting a one-step method, and performing Digital PCR detection on diluted positive virus sample RNA. The invention has the beneficial effects that: through a novel virus nucleic acid acquisition method and a Digital PCR probe method, the nucleic acid positive detection rate of the novel coronavirus 2019-nCoV infection is improved, the process specification and the standard are ensured, the influence of manual and non-standard operation on the detection result is reduced, the reliability of the result is ensured, and meanwhile, the false negative result caused by the combination of the sampling of sputum and a throat swab and the detection of a real-time fluorescence PCR method is avoided.
Description
Technical Field
The invention relates to the field of detection kits, and mainly relates to a novel coronavirus 2019-nCoV nucleic acid kit and a virus nucleic acid acquisition method.
Background
2019novel coronaviruses (2019novel coronavirus, 2019-nCoV) were named by World Health Organization (WHO) in 12.1.2020. Reliable laboratory diagnosis is a primary task to facilitate public health interventions. In acute respiratory infections, real-time PCR, i.e. RT-PCR, is commonly used to detect pathogenic viruses in respiratory secretions.
At present, the real-time fluorescent PCR method is mainly adopted to detect 2019-nCoV nucleic acid (developing a reading frame 1ab and a nucleocapsid protein) clinically to carry out early diagnosis on a case, and the diagnosis can be confirmed only if the case is positive. The samples from which they were derived included primarily sputum, as well as nasal and pharyngeal swabs with or without viral transport media. For some samples with low abundance of viral load, the fluorescence PCR method often has many false negative results due to the sensitivity, and there are many reports in practical clinical application, and the samples often need to be repeatedly sampled for 2-3 times, even patients who have positive definite diagnosis only by the 6 th pharyngeal swab nucleic acid detection, which not only increases the workload of medical staff, but also the false negative patients are easy to become infectious sources again if the false negative patients are not properly treated. Cause the low reason of detectable rate, except the limitation of fluorescence PCR method itself, more importantly because the characteristic of novel coronavirus itself, cause upper respiratory tract virus low degree such as pharynx very low, consequently we need a more effective virus sample collection divides the method, combines the absolute number that Digital PCR can direct detection nucleic acid molecule simultaneously, and its sensitivity can be down to the characteristics that single copy can be accurate carry out quantitative determination to low abundance sample to can expect to improve the detectable rate greatly. Based on the current epidemiological investigation, the incubation period of the novel coronavirus 2019-nCoV is 1-14 days, and is mostly 3-7 days. More importantly, the latent period is also infectious, and asymptomatic infectors can also become a source of infection. Therefore, a novel and high-sensitivity detection method is urgently needed, and a solution is provided for epidemic situation prevention and control.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provides a novel coronavirus 2019-nCoV nucleic acid kit and a virus nucleic acid collection method.
The object of the present invention is achieved by the following technical means. A kit for rapidly and accurately detecting novel coronavirus 2019-nCoV nucleic acid by combining a Digital PCR (polymerase chain reaction) probe method is characterized in that a specific primer and a fluorescent probe are designed for detecting the novel coronavirus 2019-nCoV nucleic acid in a sample according to the novel coronavirus 2019-nCoV ORF1ab and an N gene as amplification target regions;
Target 1(ORF1ab):
forward primer (F): CCCTGTGGGTTTTACACTTAA
Reverse primer (R): ACGATTGTGCATCAGCTGA
Fluorescent probe (P): 5'-HEX-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'
Target 2(N gene):
forward primer (F): GGGGAACTTCTCCTGCTAGAAT
Reverse primer (R): CAGACATTTTGCTCTCAAGCTG
Fluorescent probe (P): 5'-FAM-TTGCTGCTGCTTGACAGATT-BHQ 1-3'.
The invention provides a virus nucleic acid collection method, which comprises the steps of combining prepared Super premix reaction liquid A with Super premix reaction liquid B and C, carrying out Digital PCR absolute quantification on 2019-nCoV nucleic acid RNA by adopting a one-step method, carrying out Digital PCR detection on diluted positive virus sample RNA, and carrying out annealing treatment on a sample virus RNA at the temperature of 60.0 ℃ by taking the final concentration of a primer of 900nM and the final concentration of a probe of 300nM as optimal reaction concentrations and taking an ORF1ab probe and a probe of an N gene; detecting 2019-nCoV by two groups of specific probes of ORF1ab and N gene; the test result is judged according to the following steps: both HEX and FAM fluorescence channels of the sample to be detected are positive, and can be judged as 2019n-CoV virus nucleic acid positive, the positive quality control channel is positive, and the negative quality control channel is No call; on the contrary, the sample to be tested is judged to be negative.
The invention has the beneficial effects that: through a novel virus nucleic acid acquisition method and a Digital PCR probe method, the nucleic acid positive detection rate of the novel coronavirus 2019-nCoV infection is improved, the process specification and the standard are ensured, the influence of manual and non-standard operation on the detection result is reduced, the reliability of the result is ensured, and meanwhile, the false negative result caused by the combination of the sampling of sputum and a throat swab and the detection of a real-time fluorescence PCR method is avoided.
Drawings
FIG. 1 is a schematic representation of the HEX fluorescence channel copy number of the present invention.
FIG. 2 is a schematic representation of FAM fluorescence channel copy number of the present invention.
Detailed Description
The invention will be described in detail with reference to the following figures and examples:
1. design of specific primers and probes: according to the invention, a specific primer and a fluorescent probe (a sequence published by the Chinese disease prevention and control center) are designed according to the fact that the novel coronavirus 2019-nCoV ORF1ab (open reading frame 1ab) and the N gene (nucleocapsid protein) are used as amplification target regions, the specific primer and the fluorescent probe are used for detecting the novel coronavirus 2019-nCoV nucleic acid in a sample, and the detection specificity of the invention is ensured
Target 1(ORF1ab):
Forward primer (F): CCCTGTGGGTTTTACACTTAA
Reverse primer (R): ACGATTGTGCATCAGCTGA
Fluorescent probe (P): 5'-HEX-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'
Target 2(N gene):
forward primer (F): GGGGAACTTCTCCTGCTAGAAT
Reverse primer (R): CAGACATTTTGCTCTCAAGCTG
Fluorescent probe (P): 5'-FAM-TTGCTGCTGCTTGACAGATT-BHQ1-3'
According to the sequence published by the Chinese disease prevention and control center, the invention modifies different fluorescence on the probe to realize single-tube one-step detection. The above primers and probes are all inBaori doctor Tech technology (Beijing) Co Ltd (takara China)Synthesized and purified by HPLC.
2. The novel virus nucleic acid collection method comprises the following steps: gauze mask collection (containing active carbon, polypropylene and other materials)
Based on the characteristics of the 2019-nCoV novel coronavirus, the special mask is prepared to collect viruses (such as cough and the like) discharged from respiratory tracts of patients, and then the mask is rinsed by using a virus dissolving solution and then enriched, so that the abundance of virus load can be improved, and the detection rate is greatly improved.
3. Based on the experiment principle of Digital PCR, the method mainly comprises a Super premix reaction solution and a quality control product:
super premix reaction liquid A: (including hot start Taq enzyme, RT enzyme, DTT, specific primer and probe, buffer solution, etc.)
Super premix reaction solution B (oil produced by probe liquid drop)
Super premix reaction solution C (drop reader oil)
Quality control (negative quality control in Table 1 and positive quality control in Table 2)
TABLE 1 negative reference compositions
| Numbering | Components | Concentration of |
| Negative 1 | Adenoviral vectors | 1000copies/μl |
| Negative 2 | Influenza A virus | 1000copies/μl |
| Negative 3 | Respiratory syncytial virus | 1000copies/μl |
| Negative 4 | MERS coronavirus pseudovirus | 1000copies/μl |
| Negative 5 | Pseudovirus of SARS coronavirus | 1000copies/μl |
| Negative 6 | Parainfluenza virus | 1000copies/μl |
| Negative 7 | Coronavirus HKU1 | 1000copies/μl |
| Negative 8 | Coronavirus NL63 | 1000copies/μl |
| Negative 9 | Coronavirus 229E | 1000copies/μl |
| Negative 10 | Coronavirus OC43 | 1000copies/μl |
TABLE 2 Positive reference Components
| Numbering | Components | Concentration of |
| Positive 1 | 2019-nCoV pseudovirus | 1000copies/μl |
| Positive 2 | 2019-nCoV pseudovirus | 100copies/μl |
| Positive 3 | 2019-nCoV pseudovirus | 10copies/μl |
And combining the prepared Super premix reaction liquid A with the Super premix reaction liquids B and C to perform Digital PCR detection. The group is positive and negative quality control products and samples to be detected, and a proper instrument is selected and carried out according to an operation instruction.
And (3) judging a detection result: the HEX and FAM fluorescence channels of the sample to be detected are positive, the sample to be detected 2019n-CoV virus nucleic acid can be judged to be positive, the positive quality control channel is positive, and the negative quality control channel is No call. On the contrary, the sample to be tested is judged to be negative.
The invention adopts a one-step method to carry out Digital PCR absolute quantification on 2019-nCoV nucleic acid RNA, and detects 2019-nCoV through two groups of specific probes of ORF1ab and N gene. The invention also optimizes each element, and has the advantages of simpler operation, higher sensitivity, less pollution and the like.
Compared with a fluorescence PCR method, the invention detects 2019-nCoV positive samples and has the advantages of high sensitivity, low detection limit and the like.
After the laboratory virus is enriched, the RNA concentration of the positive sample is 10-1～10-7And (4) diluting in multiple proportion, and performing RT-fluorescence PCR method and RT-Digital PCR method for quantification. The quantitative results of RT-Digital PCR method are shown in Table 3, and the copy numbers of HEX (ORF1ab) fluorescence channel are respectively: 6840. 670, 69, 6.8, 5.4, 4.2, 1.6copies/μ l; copy numbers of FAM (N gene) fluorescent channels were: 6350. 640, 63, 6.6, 5.1, 4.3, 1.8copies/μ l. The CT value of the RT-fluorescence PCR amplification curve is shown in Table 4, when the dilution is 10-7, the RT-fluorescence PCR and the negative control have no obvious amplification, no CT value is displayed, therefore, the sensitivity of the RT-fluorescence PCR method is that the dilution is 10-6Concentration of positive sample, Ct value of HEX (ORF1ab) 34.77; the Ct value of FAM (N gene) was 35.45 (less than 37). And the RT-Digital PCR method is carried out under the condition that the microdroplet generation is normal and the Poisson distribution is met and the dilution degree is 10-7The copy number concentrations of the positive samples were found to be 3.6 and 3.1 copies/. mu.L, respectively. The result shows that the lowest detection limit of the RT-Digital PCR method is as low as the number of single-bit copies, and the sensitivity of the RT-Digital PCR method is higher by one order of magnitude than that of the RT-fluorescent PCR method.
TABLE 3RT-Digital PCR method results
| Sample dilution | HEX (ORF1ab) copy number | FAM (N Gene) |
| 10-1 | 6480copies/μl | 6350copies/ |
| 10-2 | 670copies/μl | 640copies/ |
| 10-3 | 69copies/μl | 63copies/ |
| 10-4 | 6.8copies/μl | 6.6copies/ |
| 10-5 | 5.4copies/μl | 5.1copies/ |
| 10-6 | 4.2copies/μl | 4.3copies/ |
| 10-7 | 1.6copies/μl | 1.8copies/μl |
TABLE 4 RT-fluorescent PCR method results
| Sample dilution | HEX (ORF1ab) CT value | FAM (N Gene) |
| 10-1 | 20.14 | 20.77 |
| 10-2 | 23.16 | 23.76 |
| 10-3 | 26.42 | 26.89 |
| 10-4 | 28.43 | 29.13 |
| 10-5 | 30.26 | 31.39 |
| 10-6 | 32.51 | 33.24 |
| 10-7 | Unknow | Unknow |
According to the invention, by detecting the 2019-nCoV positive sample, enteroviruses and adenoviruses, as shown in the table 5, the HEX copy number of the 2019-nCoV positive sample is 488 copies/. mu.l; FAM fluorescence channel copy number 465 copies/. mu.l. The detection results of the enterovirus and the adenovirus are both No Call, which shows that the invention has high specificity.
TABLE 5 2019-nCoV Positive samples, Enterovirus and adenovirus results of the invention
| RT-Digital PCR method | 2019-nCoV positive sample | Enterovirus (EV) | Adenoviral vectors |
| HEX (ORF1ab) copy number | 488copies/μl | No Call | No Call |
| FAM (N Gene) copy number | 465copies/μl | No Call | No Call |
The invention detects the same 2019-nCoV positive sample at different times, and combines the standard deviation and the relative standard deviation of the experimental result, as shown in tables 6 and 7. The results of the test sections of the invention are shown to have good reproducibility both between groups and within groups.
Table 6: HEX fluorescence channel number
| Degree of dilution | Day one | The fifth day | The tenth day | Standard Deviation (SD) | Mean value of | Relative standard deviation (RSD%) |
| 10-1 | 8763 | 8923 | 9012 | 103.02 | 8899.33 | 1.16 |
| 10-2 | 865 | 833 | 912 | 32.44 | 870.00 | 3.73 |
| 10-3 | 76 | 56 | 67 | 8.18 | 66.33 | 12.33 |
| 10-4 | 8.5 | 7.6 | 8.3 | 0.39 | 8.13 | 4.74 |
| 10-5 | 6.5 | 6.2 | 5.7 | 0.33 | 6.13 | 5.38 |
| 10-6 | 3.4 | 3.1 | 2.9 | 0.21 | 3.13 | 6.56 |
Table 7: FAM fluorescence channel number
| Degree of dilution | Day one | The fifth day | The tenth day | Standard Deviation (SD) | Mean value of | Relative standard deviation (RSD%) |
| 10-1 | 9256 | 9873 | 8903 | 400.86 | 9344.00 | 4.29 |
| 10-2 | 945 | 965 | 876 | 38.13 | 928.67 | 4.11 |
| 10-3 | 89 | 98 | 92 | 3.74 | 93.00 | 4.02 |
| 10-4 | 9.1 | 8.9 | 9.7 | 0.34 | 9.23 | 3.68 |
| 10-5 | 7.3 | 6.7 | 7.8 | 0.45 | 7.27 | 6.19 |
| 10-6 | 4.3 | 4.7 | 3.8 | 0.37 | 4.27 | 8.63 |
Examples
The specific experimental steps of the invention are as follows:
extracting virus RNA from positive specimen (TaKaRa Mini BEST Viral RNA/DNA extraction kit)
1. Splitting virus in stock solution: 200. mu.l of the virus stock solution was added with 200. mu.l of Buffer VGB and 20. mu.l of protease K, and mixed well in a 56 ℃ water bath for 10 minutes. Add 200. mu.l absolute ethanol to the lysate, suck well and mix well.
2. The Spin Column was mounted on a Collection Tube, the solution was transferred to the Spin Column, centrifuged at 12,000rpm for 2 minutes, and the filtrate was discarded.
3. Mu.l of Buffer RWA was added to the Spin Column, centrifuged at 12,000rpm for 1 minute, and the filtrate was discarded.
4. Mu.l of Buffer RWB was added to the Spin Column, centrifuged at 12,000rpm for 1 minute, and the filtrate was discarded.
5. And repeating the operation step 4.
6. Spin Column was mounted on the Collection Tube and centrifuged at 12,000rpm for 2 minutes.
7. Spin Column was mounted on a new 1.5ml RNase free collection tube, and 30-50. mu.l of RNase free dH2O was added to the center of the Spin Column membrane, and allowed to stand at room temperature for 5 minutes.
The RNA was eluted by centrifugation at 8.12,000 rpm for 2 minutes.
And 9, detecting the RNA concentration. RT-Digital PCR Experimental procedure (QX 200 PCR instrument from Bole Co.)
Droplet generation:
preparing 20 mul of probe reaction system:
| reaction system | Volume (μ l) |
| Super premix reaction solution A | 18 |
| |
2 |
Transferring the above-mentioned solution into a microdroplet-generating cartridge, adding 70. mu.l of Super premix reaction solution B of the present invention, and placing the cartridge in a microdroplet-generating apparatus AutoDGTMAbove, the droplet starts to be generated.
PCR amplification
1. The automated droplet generator removes a microtiter plate containing droplets. Seal Plate with PX1 PCR Plate Sealer
2. Performing thermocycling amplification
Droplet reading
After amplification, the 96-well plate is placed on a QX200 reader, the Super premix reaction solution C of the invention is added, and QuantSoft software is opened for droplet reading. Negative quality control substances are added into the negative control group in each experiment to replace reaction templates.
Since the optimal reaction concentrations and annealing temperatures of the primers and probes are critical to the specificity and sensitivity of the invention, the optimization of the concentration of the Digital PCR probes and the optimization of the annealing temperature of the Digital PCR are performed in the process of the invention.
Optimization of probe concentration:
according to the experimental steps, the diluted positive virus sample RNA is subjected to Digital PCR detection, and the optimal condition of the probe concentration is explored.
In the experiment, 5 different probe final concentrations of 900nM primer and 500, 400, 300, 200 and 100nM from left to right are selected respectively. As a result, as shown in Table 8, from the viewpoint of the fluorescence signal intensity, the higher the probe concentration, the stronger the copy number signal. When the concentration of ORF1ab and N gene probe is 500nM or 400nM, the reaction has too high fluorescence signal intensity and positive amplification inhibition occurs. When the concentration of the probe is 200 or 100nM, the intensity of the fluorescence signal of the reaction is weaker; thus, it was shown from the experimental results that the sample viral RNA was at the optimal response concentration with both the primer final concentration of 900nM and the probe final concentration of 300 nM.
TABLE 8 Probe concentration gradient results
| Concentration of Probe | HEX (ORF1ab) copy number | FAM (N Gene) copy number |
| 500nM | 435copies/μl | 445copies/μl |
| 400nM | 523copies/μl | 519copies/μl |
| 300nM | 786copies/μl | 762copies/μl |
| 200nM | 598copies/μl | 593copies/μl |
| 100nM | 387copies/μl | 391copies/μl |
Optimization of probe annealing temperature:
and carrying out Digital PCR detection on the diluted positive virus sample RNA according to the optimized probe concentration, and exploring the optimal condition of the probe annealing temperature.
As shown in Table 9, the ORF1ab probe was used to perform RT-Digital PCR on samples at 65.0 ℃, 63.8 ℃, 62.8 ℃, 61.5 ℃, 60.0 ℃, 57.9 ℃, 56.8 ℃ and 55.0 ℃ at different annealing temperatures. The number of droplets is plotted on the abscissa and the intensity of the fluorescence signal is plotted on the ordinate, and the number of droplets and the number of copies are read directly on Quantasoft software, and the number of copies of the samples detected in the experiment is 344, 356, 378, 398, 469, 412, 388 and 365 copies/. mu.l, respectively. The probes for the N gene had copy numbers of 354, 376, 373, 412, 508, 455, 372 and 324 copies/. mu.l, respectively, under the same annealing temperature gradient. The results show that the copy number of the detected sample is the highest when the temperature of the ORF1ab probe and the N gene is 60.0 ℃, so that the optimal annealing temperature of the reaction is 60.0 ℃, and the reliability of the invention is greatly improved.
TABLE 9 Probe annealing temperature gradient results
The linear analysis and the determination of the lowest detection limit of the invention:
after extracting the RNA of the nucleic acid virus, the RNA is quantified by a NanoDrop Lite ultraviolet spectrophotometer, the concentration is 3.56 × 106 copies/mu l, the RNA is used as a standard substance to be diluted by 10 times, the concentration is S0-S7:3.56 × 106, 3.56 × 105, 3.56 × 104, 3560, 356, 35.6, 3.5 copies/mu l.RT-Digital PCR detection is carried out, the copy numbers of the HEX fluorescence channel and the FAM fluorescence channel are shown in table 10, LOG10 with the copy number of the standard substance is used as a vertical coordinate, the linear equation of the HEX fluorescence channel for RT-Digital PCR detection is y 1.0519x-0.4262, the correlation coefficient R2 is 0.9987, the linear equation of the FAM fluorescence channel for detection is y 1.0205x-0.3296, the correlation coefficient R2 is 0.9989, the linear relation is good, the invention is shown in a figure, the invention, the results can be determined by the quantitative result that the virus is detected by the linear equation of y-1.0205 x fluorescence channel, and the PCR detection is determined by the linear equation of the PCR method of the virus is the range of the virus of the NanoDrop V-9.
| S0 | S1 | S2 | S3 | S4 | S5 | S6 | S7 |
| Standard substance (copies/ul) | 3.56X106 | 3.56X105 | 3.56X104 | 3560 | 356 | 35.6 | 3.56 |
| HEX(copies/ul) | No call | 214563 | 24567 | 2214 | 212 | 18 | 1.13 |
| FAM(copies/ul) | No call | 196534 | 23234 | 1787 | 198 | 22 | 1.43 |
TABLE 10 Linear analysis and minimization of Standard
And (3) clinical specimen verification:
1. comparison of detection methods
The built Digital PCR system is utilized to carry out 2019-nCoV virus nucleic acid detection on clinical specimens. The same patient collects three times of throat swab specimens every 2 days, extracts viral RNA, and then respectively performs RT-fluorescence PCR method and RT-Digital PCR method to quantify viral nucleic acid. As shown in Table 11, the results of the two previous detections by RT-fluorescent PCR method showed no fluorescent signal; and when the sample collected for the third time is detected, HEX and FAM both have fluorescence amplification signals, the CT values are 33.56 and 32.22, and the sample virus nucleic acid is positive. According to the experimental steps of the invention, the detection result of the RT-Digital PCR method shows that the 3-time collected samples are all positive for virus nucleic acid, but the copy numbers of the viruses in the first two times are lower, and the HEX (ORF1ab) fluorescence channels are respectively 1.7 copies/mu l and 2.1 copies/mu l as shown in Table 12; the FAM (N gene) fluorescence channels were 1.9 copies/. mu.l and 2.3 copies/. mu.l, respectively. HEX (ORF1ab) in the third sample was 14.4 copies/. mu.l; FAM (N gene) was 13.2 copies/. mu.l. The invention has higher sensitivity and is important for early screening of epidemic situations.
TABLE 11 clinical specimen fluorescence PCR method test results
| Specimen collection | For the first time | For the second time | The third time |
| HEX (ORF1ab) CT value | Unknow | Unknow | 33.56 |
| FAM (N Gene) CT value | Unknow | Unknow | 32.22 |
TABLE 12 clinical specimen fluorescence PCR method detection results
| Specimen collection | For the first time | For the second time | The third time |
| HEX (ORF1ab) copy number | 1.7copies/μl | 4.1copies/μl | 14.4copies/μl |
| FAM (N Gene) copy number | 1.9copies/μl | 4.3copies/μl | 13.2copies/μl |
2. Comparison of specimen collections
The same patient in clinic respectively adopts a throat swab, sputum and the mask virus enrichment method. After the special mask is worn for 2 hours, virus RNA is rinsed and enriched, and then an RT-Digital PCR method is carried out to quantify the virus nucleic acid. As shown in the results of Table 13, the mask specimen enrichment method provided by the invention has the advantages that the copy numbers of the HEX (ORF1ab) fluorescence channel and the FAM (N gene) fluorescence channel are far greater than those of the throat swab and sputum specimen, so that the virus load abundance is greatly improved, and the 2019-nCoV virus nucleic acid detection sensitivity of the invention, namely the clinical specimen sputum and the mask enrichment method provided by the invention, are improved
| Specimen collection method | Throat swab | Sputum | Enrichment method for mask |
| HEX (ORF1ab) copy number | 3.5copies/μl | 5.8copies/μl | 25.4copies/μl |
| FAM (N Gene) copy number | 3.2copies/μl | 6.1copies/μl | 25.3copies/μl |
Through multiple experimental optimization, the method for detecting the nucleic acid absolute quantification of the 2019-nCoV virus by the one-step Digital PCR method is established on the basis of the mask specimen enrichment method, reduces the possible pollution in the two-step method and the fluorescence quantitative PCR method, and has the advantages of strong specificity, high sensitivity, low detection limit and the like. Has important significance for the detection, prevention and control of epidemic situations and the like.
It should be understood that equivalent substitutions and changes to the technical solution and the inventive concept of the present invention should be made by those skilled in the art to the protection scope of the appended claims.
Claims (2)
1. A novel coronavirus 2019-nCoV nucleic acid kit, which is characterized in that: according to the new coronavirus 2019-nCoV ORF1ab and the N gene as amplification target regions, designing a specific primer and a fluorescent probe for detecting the new coronavirus 2019-nCoV nucleic acid in a sample;
Target 1(ORF1ab):
forward primer (F): CCCTGTGGGTTTTACACTTAA
Reverse primer (R): ACGATTGTGCATCAGCTGA
Fluorescent probe (P): 5'-HEX-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'
Target 2(N gene):
forward primer (F): GGGGAACTTCTCCTGCTAGAAT
Reverse primer (R): CAGACATTTTGCTCTCAAGCTG
Fluorescent probe (P): 5'-FAM-TTGCTGCTGCTTGACAGATT-BHQ 1-3'.
2. A method for collecting viral nucleic acids using the novel coronavirus 2019-nCoV nucleic acid kit of claim 1, wherein: performing Digital PCR absolute quantification on 2019-nCoV nucleic acid RNA by adopting a one-step method, performing Digital PCR detection on diluted positive virus sample RNA, and performing annealing treatment on the ORF1ab probe and the probe of the N gene at the temperature of 60.0 ℃ by taking 900nM primer final concentration and 300nM probe final concentration of sample virus RNA as optimal reaction concentrations; detecting 2019-nCoV by two groups of specific probes of ORF1ab and N gene; the test result is judged according to the following steps: both HEX and FAM fluorescence channels of the sample to be detected are positive, and can be judged as 2019n-CoV virus nucleic acid positive, the positive quality control channel is positive, and the negative quality control channel is No call; on the contrary, the sample to be tested is judged to be negative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010141882.9A CN111378783A (en) | 2020-03-04 | 2020-03-04 | Novel coronavirus 2019-nCoV nucleic acid kit and virus nucleic acid collection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010141882.9A CN111378783A (en) | 2020-03-04 | 2020-03-04 | Novel coronavirus 2019-nCoV nucleic acid kit and virus nucleic acid collection method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111378783A true CN111378783A (en) | 2020-07-07 |
Family
ID=71221395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010141882.9A Pending CN111378783A (en) | 2020-03-04 | 2020-03-04 | Novel coronavirus 2019-nCoV nucleic acid kit and virus nucleic acid collection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111378783A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111139317A (en) * | 2020-03-13 | 2020-05-12 | 欧陆分析技术服务(苏州)有限公司 | Multiplex fluorescent quantitative PCR detection kit and detection method for SARS-COV-2 virus |
| CN111733291A (en) * | 2020-07-20 | 2020-10-02 | 中山大学达安基因股份有限公司 | Method and kit for detecting novel coronavirus nucleic acid by digital PCR (polymerase chain reaction) |
| CN111944927A (en) * | 2020-08-04 | 2020-11-17 | 中国医科大学附属盛京医院 | New coronavirus nucleic acid 10-in-1 mixed mining detection technology |
| CN112029903A (en) * | 2020-08-13 | 2020-12-04 | 湖北大学 | Primer group and kit for SARS-CoV-2 virus nucleic acid detection and application thereof |
| CN112331270A (en) * | 2021-01-04 | 2021-02-05 | 中国工程物理研究院激光聚变研究中心 | Construction method of novel coronavirus Raman spectrum data center |
| CN112831607A (en) * | 2021-03-05 | 2021-05-25 | 上海伯杰医疗科技有限公司 | Novel coronavirus 2019-nCoV primer probe combination, nucleic acid detection kit and kit using method thereof |
| CN112979737A (en) * | 2021-03-01 | 2021-06-18 | 通用生物系统（安徽）有限公司 | Method for reducing fluorescence background of Taqman probe |
| CN113186346A (en) * | 2021-05-08 | 2021-07-30 | 北京华诺奥美医学检验实验室有限公司 | Novel coronavirus nucleic acid PCR-colloidal gold immunochromatography detection kit |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103484565A (en) * | 2013-09-02 | 2014-01-01 | 湖北朗德医疗科技有限公司 | Kit for detecting coronavirus through real-time fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) and application thereof |
| CN106636460A (en) * | 2016-10-21 | 2017-05-10 | 四川出入境检验检疫局检验检疫技术中心 | Nucleic acid combination for detecting pseudorabies virus and application of nucleic acid combination, and kit and method for detecting pseudorabies virus |
-
2020
- 2020-03-04 CN CN202010141882.9A patent/CN111378783A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103484565A (en) * | 2013-09-02 | 2014-01-01 | 湖北朗德医疗科技有限公司 | Kit for detecting coronavirus through real-time fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) and application thereof |
| CN106636460A (en) * | 2016-10-21 | 2017-05-10 | 四川出入境检验检疫局检验检疫技术中心 | Nucleic acid combination for detecting pseudorabies virus and application of nucleic acid combination, and kit and method for detecting pseudorabies virus |
Non-Patent Citations (2)
| Title |
|---|
| 病毒病所: "新型冠状病毒核酸检测引物和探针序列（Specific primers and probes for detection 2019 novel coronavirus", 病毒病所 * |
| 高丽霞: "分子生物学技术与实践应用研究", 中国原子能出版社 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111139317A (en) * | 2020-03-13 | 2020-05-12 | 欧陆分析技术服务(苏州)有限公司 | Multiplex fluorescent quantitative PCR detection kit and detection method for SARS-COV-2 virus |
| CN111733291A (en) * | 2020-07-20 | 2020-10-02 | 中山大学达安基因股份有限公司 | Method and kit for detecting novel coronavirus nucleic acid by digital PCR (polymerase chain reaction) |
| CN111944927A (en) * | 2020-08-04 | 2020-11-17 | 中国医科大学附属盛京医院 | New coronavirus nucleic acid 10-in-1 mixed mining detection technology |
| CN112029903A (en) * | 2020-08-13 | 2020-12-04 | 湖北大学 | Primer group and kit for SARS-CoV-2 virus nucleic acid detection and application thereof |
| CN112029903B (en) * | 2020-08-13 | 2021-11-16 | 湖北大学 | Primer group and kit for SARS-CoV-2 virus nucleic acid detection and application thereof |
| CN112331270A (en) * | 2021-01-04 | 2021-02-05 | 中国工程物理研究院激光聚变研究中心 | Construction method of novel coronavirus Raman spectrum data center |
| CN112979737A (en) * | 2021-03-01 | 2021-06-18 | 通用生物系统（安徽）有限公司 | Method for reducing fluorescence background of Taqman probe |
| CN112831607A (en) * | 2021-03-05 | 2021-05-25 | 上海伯杰医疗科技有限公司 | Novel coronavirus 2019-nCoV primer probe combination, nucleic acid detection kit and kit using method thereof |
| CN113186346A (en) * | 2021-05-08 | 2021-07-30 | 北京华诺奥美医学检验实验室有限公司 | Novel coronavirus nucleic acid PCR-colloidal gold immunochromatography detection kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111378783A (en) | Novel coronavirus 2019-nCoV nucleic acid kit and virus nucleic acid collection method | |
| Chan et al. | Human metapneumovirus detection in patients with severe acute respiratory syndrome | |
| CN105624335B (en) | A kind of kit of genetic test Middle East respiration syndrome coronavirus | |
| CN111187858A (en) | Novel coronavirus detection kit | |
| CN111394519B (en) | Novel coronavirus nucleic acid quantitative detection kit based on digital PCR and application | |
| CN102732638B (en) | Method for single-tube multiplex fluorescent polymerase chain reaction (PCR) detection of human coronavirus OC43, 229E, NL63, HKU1 and SARS, and primers, probes and kit adopted by the method | |
| CN112063756B (en) | Method and kit for multiple detection of respiratory virus nucleic acid | |
| CN107475446B (en) | Multiplex PCR detection method for simultaneously detecting multiple respiratory viruses, probe set and kit thereof | |
| CN111321251A (en) | Composition, kit, method and application for detecting and typing pathogens causing respiratory tract infection | |
| CN103642941A (en) | Quantitative detection kit of hepatitis B virus (HBV) nucleic acid | |
| CN107245531B (en) | Diarrhea pathogen multiple gene detection system and kit and application thereof | |
| CN103074449B (en) | Kit for synchronously detecting thirteen diarrhea viruses and detection method of kit | |
| WO2021212523A1 (en) | Primer pair, probe and kit for detecting sars-cov-2 by means of using nested rpa technology and use thereof | |
| CN112410470A (en) | Novel nucleic acid rapid detection kit for coronavirus, influenza A virus and influenza B virus | |
| CN109517927A (en) | A kind of A type, influenza B virus rapid typing detection reagent box and its application | |
| CN107083446B (en) | Diarrhea pathogenic bacteria multiple gene detection system and kit and application thereof | |
| Shirato et al. | An ultra-rapid real-time RT-PCR method using the PCR1100 to detect Severe Acute Respiratory Syndrome Coronavirus-2 | |
| CN101550454B (en) | Real-time fluorescence PCR reagent kit for human metapneumovirus | |
| US20230203603A1 (en) | Rt-pcr detection reagent for detecting novel coronavirus, kit and detection method thereof | |
| CN112410465A (en) | Novel coronavirus SARS-CoV-2ORF1ab and N gene constant temperature amplification primer group and kit | |
| CN105936945A (en) | Multiplex reverse transcription PCR kit for detecting four respiratory viruses | |
| CN110760614B (en) | Method for quickly detecting, parting and tracing dengue virus nucleic acid | |
| CN112029901A (en) | Reagent for improving specificity of nucleic acid amplification reaction, nucleic acid amplification reaction solution and kit | |
| CN113549708A (en) | POCT mode-based novel coronavirus COVID-19 rapid detection kit | |
| Belliot et al. | Characterization of ‘Norwalk-like viruses’ and astroviruses by liquid hybridization assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200707 |